On Tuesday, Shares of Nordic American Tanker Ltd (NYSE:NAT), lost -2.92% to $16.30.
Nordic American Tankers Limited, declared that it had reached a contract to acquire two 2010 built ships for delivery to NAT in September and October 2015. The first of these vessels was taken over recently and has been renamed “Nordic Light”.
The delivery of its sister ship is predictable to take place during October. Thereafter, the Company will have a fleet of 26 Suezmax vessels counting two new buildings to be delivered in August 2016 and in early 2017.
Going forward, NAT is seeking to improvement its dividend and earnings capacity through further expansion when the time is right to do so. We believe that our strong balance sheet and our well defined and transparent operating model, counting quarterly dividend payments, give the Company a strong competitive position.
Nordic American Tankers Limited, a tanker company, engages in acquiring and chartering double-hull tankers. As of December 31, 2014, it owned 24 Suezmax crude oil tankers, counting two new buildings under construction. The company was founded in 1995 and is based in Hamilton, Bermuda.
Shares of Cameron International Corporation (NYSE:CAM), inclined 2.07% to $65.11, during its last trading session.
Cameron, declared that, in accordance with its formerly revealed succession plan, R. Scott Rowe has assumed the role of President and Chief Executive Officer, effective recently.
Rowe has served with Cameron for 13 years, most recently as President and Chief Operating Officer. He formerly served as Chief Executive Officer of OneSubsea, the company’s joint venture with Schlumberger Limited. He had also formerly served as President of the Company’s Subsea Systems division and President of the Engineered and Process Valves business in the Company’s Valves and Measurement segment. He is also a member of Cameron’s board of directors. Rowe is an Engineering Administration graduate from the US Military Academy at West Point and holds an MBA from Harvard Business School.
Rowe replaces Jack B. Moore, who is retiring as the company’s Chief Executive Officer. Moore joined the company in 1999 after a 23-year career at Baker Hughes Incorporated. At Cameron, he held a series of progressively responsible positions in operations before becoming CEO in 2008. He continues to serve as Chairman of the Board of Cameron.
Cameron International Corporation provides flow equipment products, systems, and services worldwide. The company’s Subsea segment offers integrated solutions, products, systems, and services to the subsea oil and gas market, counting integrated subsea production systems involving wellheads, subsea trees, manifolds and flowline connectors, and subsea processing systems.
At the end of Tuesday’s trade, Shares of Sanofi SA (ADR) (NYSE:SNY), lost -0.67% to $48.86.
Genzyme, a Sanofi company, declared a new global initiative, vs.MS, that is designed to raise awareness of the often unspoken emotional and physical burden of relapsing multiple sclerosis (RMS) on people living with the disease and their care partners. To better understand the full burden associated with RMS, Genzyme fielded a global survey among more than 1,500 people living with RMS and their care partners across seven countries. An initial set of data from the vs.MS global survey will be shared for the first time at the 31st Congress of the European Committee on the Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, October 7-10.
“As part of our ongoing commitment to assist improve the lives of people living with MS, we are proud to introduce this new global initiative in partnership with patients and caregivers,” said Darlene Jody, Head of MS Medical Affairs at Genzyme. “At Genzyme, we believe that when we know more, we can do more. The experiences uncovered through the vs.MS survey will assist shed light on the physical and emotional toll RMS can have, and we look forward to developing a program that may assist drive a more open exchange for better informed care.”
While at ECTRIMS, Genzyme is bringing together thought leaders from across the MS Community representing people living with MS, healthcare providers specializing in the disease, and advocacy groups to review the full vs.MS survey findings and start developing a program that will be rolled out to the community.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
Finally, Splunk Inc (NASDAQ:SPLK), ended its last trade with -0.02% loss, and closed at $55.29.
Splunk, declared the new release of the Splunk App for AWS at AWS re:Invent 2015. The new version of the app transforms AWS CloudTrail, AWS Config, Amazon CloudWatch, and now Amazon Virtual Private Cloud (Amazon VPC) Flow Logs into easy-to-use dashboards that provide comprehensive security, compliance and operational insights into Amazon Web Services (AWS) environments.
“The new Splunk App for AWS provides leading enterprises with additional visibility and security as they move mission critical workloads to the cloud with confidence,” said Marc Olesen, senior vice president of cloud solutions, Splunk. “As they efficiently and productively deploy and manage AWS environments, enterprises benefit from end-to-end visibility and the ability to monitor user activity, resource changes, topology and network traffic flows. We are excited to show organizations how this can be done with Splunk cloud solutions at AWS re:Invent 2015.”
Splunk, Inc. provides software products that enable organizations to gain real-time operational intelligence in the United States and internationally. The company’s products enable users to collect, index, search, explore, monitor, and analyze data regardless of format or source users.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
